{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '20. Known active human immunodeficiency virus (HIV) infection or HIV seropositivity.', '21. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus', 'ribonucleic acid (RNA) or hepatitis B virus surface antigen.', \"22. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow\", 'tablets, or any active gastrointestinal dysfunction that could interfere with absorption of', 'study treatment.', '23. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion', 'of the Investigator, could interfere with treatment, compliance, or the ability to give', 'informed consent.', '24. Contraindication to any of the required concomitant drugs or supportive treatments.', '25. Patients unwilling or unable to comply with the protocol, including providing 24-hour', 'urine samples for urine protein electrophoresis at the required time points.', 'Confidential', 'Page 54', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '8.', 'REGISTRATION AND RANDOMIZATION', '8.1.', 'Screening and Registration', 'The Screening period will start once a patient has provided written informed consent to', 'participate in the study and ends on the day of study entry (C1D1).', 'Patient enrollment information will be provided by the site to Karyopharm for evaluation and', 'approval. Upon confirmation of key eligibility criteria, Karyopharm will approve enrollment of', 'the patient. After approval by Karyopharm, the patient may be randomized. See Section 8.2 for', 'randomization procedures.', '8.1.1.', 'Study Patient Number', 'Each patient will be assigned a unique patient number and will keep this number for the duration', 'of the study. Patient numbers will not be reassigned or reused for any reason. Patients will be', 'identified to the Sponsor by their assigned number, date of birth, and sex. The Investigator must', 'maintain a patient master log.', '8.1.2.', 'Rescreening', 'Rescreening is permitted in this study. If a patient fails any of the inclusion or exclusion criteria,', 'a patient may be rescreened after a suitable period of time (the exact length is dependent upon', 'the reason for the screen failure) per the documented agreement of Karyopharm and the', 'Investigator. Any patient who is rescreened must be reconsented and will retain the same patient', 'number. A patient may only fail screening once.', '8.1.3.', 'Screen Failures', 'A Screen Failure is defined as any patient who signs the informed consent form (ICF) but who is', 'not randomized into the study. The reason for not randomizing the patient will be entered in the', 'electronic case report form (eCRF). The demographic information, informed consent, and', 'inclusion/exclusion pages must also be completed for screen failure patients. No other data will', 'be entered into the clinical database for patients who are screen failures, unless the patient', 'experiences a serious adverse event (SAE) during the Screening period.', '8.1.4.', 'Replacement of Patients', 'Patients who withdraw from the study without completing at least 1 cycle due to reasons that are', 'unrelated to study treatment and/or disease state may be replaced.', '8.2.', 'Randomization to Study Treatment', 'An Interactive Response Technology system will be used to perform treatment randomization.', 'Patients will be randomized to a treatment arm in a block of randomization codes that have been', \"assigned to the patient's country and stratum.\", 'Randomization will be performed prior to dosing.', 'Randomization will be stratified based on the following stratification factors and will maintain', 'the 1:1 allocation between treatment arms (SVd, Vd) within each of the stratification categories:', 'Confidential', 'Page 55', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Prior PI therapies (Yes or No)', 'Number of prior anti-MM regimens (1 versus >1)', 'R-ISS stage based on screening results (R-ISS Stage III versus R-ISS Stage I or II)', '(Palumbo 2015) (Table 14). If data for CA and serum LDH required for R-ISS', 'staging are not available, patients will be assigned to the R-ISS category', 'corresponding to their ISS stage.', 'It is planned to randomize patients within individual countries in a 1:1 allocation to SVd:Vd.', 'Table 14:', 'Revised International Staging System for Multiple Myeloma', 'Prognostic Factor', 'Criteria', 'ISS Stage', 'Stage I', '2-microglobulin < 3.5 mg/L, serum albumin >3.5 g/dL', 'Stage II', 'Not ISS Stage I or III', 'Stage III', '2-microglobulin >5.5 mg/L', 'CA by iFISH', 'High Risk', 'Presence of del(17p), and/or translocation t(4;14), and/or', 'translocation t(14;16)', 'Standard Risk', 'No high-risk CA', 'LDH', 'Normal', 'Serum LDH < the upper limit of normal', 'High', 'Serum LDH > the upper limit of normal', 'R-ISS Stage', 'I', 'ISS Stage I and standard-risk CA by iFISH and normal LDH', 'II', 'Not R-ISS Stage I or III', 'III', 'ISS Stage III and either high-risk CA by iFISH or high LDH', 'Abbreviations: CA = chromosomal abnormalities; iFISH = interphase fluorescent in situ hybridization;', 'ISS = International Staging System; LDH = lactate dehydrogenase; R-ISS = Revised International Staging System.', 'Source: (Palumbo 2015).', '8.3.', 'Blinding Procedures', 'Not applicable, this is an open-label study.', 'Confidential', 'Page 56', 'Version 4.0']\n\n###\n\n", "completion": "END"}